Skip to main content
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published loading...Updated

Australia Prepares Swift Reforms to PBS Listing as Trump Threatens 250% Drug Tariffs

AUSTRALIA, AUG 6 – Industry leaders warn excessive wait times for new medicines on Australia's Pharmaceutical Benefits Scheme could delay treatments by up to 22 months, posing a greater risk than US tariffs.

  • The Australian government is advancing reforms to speed up listing medicines on the Pharmaceutical Benefits Scheme amid US tariff threats.
  • The reforms follow a Health Technology Assessment review delivered last year that recommended streamlining the PBS process to improve access.
  • US President Donald Trump has imposed tariffs on pharmaceuticals, threatening to raise them to 250 per cent unless drugs are made in America.
  • Mr Trump told CNBC, "it's going to go to 150 per cent and then it's going to go to 250 per cent" reflecting his push for domestic production.
  • Australia aims to improve drug approval speed and protect the PBS, which remains off limits to trade negotiations despite US industry pressure.
Insights by Ground AI
Does this summary seem wrong?

9 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 43% of the sources lean Left, 43% of the sources lean Right
43% Right

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Australian Financial Review broke the news in Sydney, Australia on Wednesday, August 6, 2025.
Sources are mostly out of (0)
News
For You
Search
BlindspotLocal